News Sentiment

PSNL sentiment intelligence

Personalis Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 14.07 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+3.3% over one week, +46.7% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Personalis draws takeover interest from Merck (PSNL:NASDAQ)

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction 3.3% Price confirming higher
Trend fit Trend active 46.7% over four weeks
Fair value 195.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 29
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
Investing.com 5
TradingView 5
MT Newswires 4
Moomoo 4
Market source 4
Investing.com Nigeria 3
Simply Wall Street 3

Event Lens

What the news is about

Classified themes
Market update 31
Analyst action 7
Regulatory and legal 7
Earnings 4
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
TradingView Direct company coverage

Why Is PSNL Stock Up 5% After-Hours?

Shares of Personalis (PSNL) rose 5% after-hours following rumors that the precision oncology company is exploring strategic options, including a potential sale, due to takeover interest from Merck & Co. (MRK) and other parties. Personalis has hired investment banks and a law firm

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 23:40
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Personalis Inc For: 15 July By Investing.com

This article announced a Form 4 filing for Personalis Inc. (PSNL) on July 15th, 2026, noting that the stock was up 5.06% at the time of publication. The brief piece serves as a notice of the regulatory filing.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
16 Jul 2026 01:10
Source
Investing.com Nigeria
Stock Titan Direct company coverage

[144] Personalis, Inc. SEC Filing

This article details a Form 144 SEC filing by Personalis, Inc. (PSNL), indicating a proposed sale of 100,000 shares of common stock with an aggregate market value of $1,503,000. The shares were acquired through the exercise of stock options on July 15, 2026, and the sale is expec

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 20:42
Source
Stock Titan
Investing.com Direct company coverage

Personalis president and CMO Richard Chen sells $1.5m in stock

Richard Chen, President and Chief Medical Officer of Personalis, Inc., sold 100,000 shares of company stock for $1.515 million after exercising options. The transaction was executed under a Rule 10b5-1 trading plan. The sale occurred as PSNL trades near its 52-week high, though I

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 19:33
Source
Investing.com
Moomoo Direct company coverage

PERSONALIS INC : TD COWEN RAISES TARGET PRICE TO $18 FROM $10

TD Cowen has increased its price target for Personalis Inc. (PSNL) shares from $10 to $18, while maintaining a "Buy" rating on the stock. This adjustment reflects a more optimistic outlook on the company's future stock performance.

Tone
Positive 71/100
Event
Analyst action
Published
15 Jul 2026 16:10
Source
Moomoo
Simply Wall Street Direct company coverage

How UKCA Approval of NeXT Personal Dx Could Reshape Personalis’ (PSNL) Cross‑Border Cancer Trial Role

Personalis, Inc. recently received UKCA marking for its NeXT Personal Dx ultrasensitive MRD test, enabling its use in England, Wales, and Scotland, and has partnered with Link Medical Solutions for commercialization. This approval positions NeXT Personal Dx as a unified platform

Tone
Neutral 50/100
Event
Regulatory and legal
Published
14 Jul 2026 21:42
Source
Simply Wall Street
Investing.com Direct company coverage

Personalis receives UK regulatory clearance for cancer test

Personalis Inc. has received UKCA marking for its NeXT Personal Dx test, allowing clinical use of its minimal residual disease detection technology in England, Wales, and Scotland. This regulatory clearance enables pharmaceutical companies to use the platform in multinational cli

Tone
Positive 72/100
Event
Regulatory and legal
Published
14 Jul 2026 10:42
Source
Investing.com
Stock Titan Direct company coverage

Cancer Test for Small DNA Traces Can Now Be Used in Great Britain

Personalis, Inc. (Nasdaq: PSNL) has received UKCA marking for its NeXT Personal Dx test, allowing its advanced Minimal Residual Disease (MRD) detection technology to be used clinically across Great Britain. This regulatory milestone enables earlier cancer recurrence detection for

Tone
Positive 89/100
Event
Regulatory and legal
Published
14 Jul 2026 09:42
Source
Stock Titan
Market source Direct company coverage

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

Personalis, Inc. has achieved UKCA marking for its NeXT Personal Dx test, allowing the clinical use of its ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Britain. This regulatory milestone not only expands patient access to advanced cancer diagnos

Tone
Positive 74/100
Event
Regulatory and legal
Published
14 Jul 2026 06:00
Source
Market source
StocksToTrade Direct company coverage

PSNL Stock Climbs As Morgan Stanley Lifts Price Target

Personalis Inc. (PSNL) saw its stock climb by 10.2% after Morgan Stanley raised its price target from $9 to $13, signaling increased expectations ahead of the company's next earnings report. Despite the company's significant losses and negative profit margins, its strong liquidit

Tone
Positive 71/100
Event
Earnings
Published
13 Jul 2026 16:39
Source
StocksToTrade
TradingView Direct company coverage

Enterprise value to EBITDA forward of Personalis, Inc. – HAM:04X

The article displays the enterprise value to EBITDA forward for Personalis, Inc. (HAM:04X) on the TradingView platform. It provides financial data and market information related to the company's stock on the Hamburg Stock Exchange. The content is presented within the context of T

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 00:11
Source
TradingView
Kavout | AI Direct company coverage

Personalis's Clinical Growth Story Faces a Reality Check as CEO Sells Millions

Personalis (PSNL) stock has surged over 100% in the last year due to strong clinical growth and Medicare coverage for its NeXT Personal MRD test, pushing its market cap to $1.25 billion. However, CEO Christopher Hall recently sold over $2.8 million in stock, raising questions abo

Tone
Negative 36/100
Event
Market update
Published
10 Jul 2026 21:39
Source
Kavout | AI
Moomoo Direct company coverage

Personalis Insider Sold Shares Worth $1,508,000, According to a Recent SEC Filing

This article reports on a recent SEC filing indicating that an insider at Personalis sold shares valued at $1,508,000. Further details from the SEC filing would provide context on the specific insider, the number of shares, and the transaction date. This information is typically

Tone
Negative 20/100
Event
Market update
Published
10 Jul 2026 08:10
Source
Moomoo
Stock Titan Direct company coverage

Personalis (PSNL) CEO trades 100,000 shares via 10b5-1 plan and option exercise

Personalis, Inc. CEO Christopher M. Hall reported exercising options for 100,000 shares at $1.61 each and subsequently selling those 100,000 shares at a weighted average price of $15.08 per share. These transactions, executed on July 9, 2026, were part of a pre-arranged Rule 10b5

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 01:09
Source
Stock Titan
Simply Wall Street Direct company coverage

Personalis (PSNL) Stock Looks Rich Even After A Very Large Run

Personalis (PSNL) stock has seen a significant 3-year gain, returning roughly 5x, yet its current valuation appears expensive based on fundamental checks. The company trades at a Price-to-Sales (P/S) ratio of 22.9x, far exceeding the industry average of 3.9x and a modelled fair P

Tone
Negative 20/100
Event
Market update
Published
09 Jul 2026 21:39
Source
Simply Wall Street
Stock Titan Direct company coverage

Morgan Stanley Smith Barney (PSNL) files Rule 144 to sell 100,000 shares on 07/09/2026

Morgan Stanley Smith Barney LLC filed a Rule 144 notice to sell 100,000 shares of Personalis, Inc. (PSNL) common stock, valued at $1,411,000. This proposed sale on July 9, 2026, follows the exercise of stock options for cash. The filing also details recent 10b5-1 sales by Christo

Tone
Neutral 50/100
Event
Balance sheet
Published
09 Jul 2026 20:09
Source
Stock Titan
GuruFocus Direct company coverage

PSNL Maintained by Morgan Stanley -- Price Target Raised to $13.

Morgan Stanley has maintained an Equal-Weight rating on Personalis (PSNL) but raised its price target from $9.00 to $13.00, an increase of 44.44%. Despite this, GuruFocus assesses PSNL as significantly overvalued by 614.7%, with a current price of $14.87 against a GF Value™ of $2

Tone
Negative 40/100
Event
Analyst action
Published
09 Jul 2026 18:09
Source
GuruFocus
TradingView Direct company coverage

Personalis, Inc. Stock 12‑Month Price Target Raised to $11.43, Implies 19% Downside

Analysts have raised the 12-month average price target for Personalis, Inc. (PSNL) stock from $10.86 to $11.43, with individual forecasts ranging from $10 to $13 per share. Despite this increase, the new target implies a potential 19% downside based on the most recent closing pri

Tone
Negative 40/100
Event
Analyst action
Published
09 Jul 2026 13:09
Source
TradingView
Investing.com Direct company coverage

Personalis stock hits 52-week high at 14.24 USD

Personalis Inc. (PSNL) stock reached a new 52-week high of $14.24, reflecting a significant 1-year increase of 107.19%. Despite this surge and strong investor confidence, InvestingPro analysis suggests the stock might be overvalued, although three analysts have revised earnings u

Tone
Positive 65/100
Event
Earnings
Published
06 Jul 2026 15:12
Source
Investing.com
Simply Wall Street Direct company coverage

Is Personalis (PSNL) Fully Valued Following Its Sharp Share Price Run?

Personalis (PSNL) has seen significant share price appreciation over various timeframes but continues to report net losses, raising questions about its current valuation. While the company is involved in strategic partnerships and operational improvements, a common narrative sugg

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 04:56
Source
Simply Wall Street
Investing.com Nigeria Direct company coverage

Form 4 Personalis Inc For: 29 June By Investing.com

This article from Investing.com reports the filing of a Form 4 for Personalis Inc. on June 29th. The content is brief, primarily serving as an announcement of the filing and referencing the company's stock symbol PSNL. The article appears to be an automated notification from Inve

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 17:41
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Personalis (PSNL) CFO trades 4,982 shares under Rule 10b5-1 plan

Personalis, Inc. CFO and COO Aaron Tachibana reported an exercise-and-sell transaction involving 4,982 shares of company stock. He exercised stock options at $5.32 per share and subsequently sold the shares in an open-market sale for $14.00 per share. These transactions were exec

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 07:39
Source
Stock Titan
Stock Titan Direct company coverage

PSNL (NASDAQ: PSNL) files Rule 144 to sell 4,982 shares via option exercise

Personalis, Inc. (PSNL) filed a Rule 144 notice to sell 4,982 shares of Common Stock through an option exercise scheduled for June 29, 2026. The filing also detailed prior 10b5-1 sales by Aaron Tachibana, totaling 129,050 shares across three trades in May-June 2026, with an aggre

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 00:39
Source
Stock Titan